Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

statnews.com/2025/06/23/amgen-maritide-obesity-drug-trial-discontinuations-side-effects-dosing-changes

CHICAGO — Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a mid-stage trial, results that support the company’s decision to use a slower dosing schedule to make the drug more tolerable in further testing.
In the…

This story appeared on statnews.com, 2025-06-23 21:04:55.255000.
The Entire Business World on a Single Page. Free to Use →